EHA 2024 | The current role of plasmapheresis in the treatment landscape for TTP
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses the current role of plasmapheresis in the treatment landscape of thrombotic thrombocytopenic purpura (TTP). While plasmapheresis has been the standard of care for this disease for the last decade, new drugs such as caplacizumab for immune or acquired TTP or recombinant ADAMTS13 for congenital TTP have shown great promise and are currently undergoing trials to determine whether they could replace plasma exchange therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
